These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30030468)

  • 1. CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide.
    Yang F; Xiong X; Liu Y; Zhang H; Huang S; Xiong Y; Hu X; Xia C
    Sci Rep; 2018 Jul; 8(1):10994. PubMed ID: 30030468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.
    Yang F; Liu L; Chen L; Liu M; Liu F; Xiong Y; Hu X; Xia C
    Sci Rep; 2018 Dec; 8(1):18063. PubMed ID: 30584236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs.
    Xu H; Murray M; McLachlan AJ
    Curr Drug Metab; 2009 Jul; 10(6):643-58. PubMed ID: 19799532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
    Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
    Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
    Yoo HD; Kim MS; Cho HY; Lee YB
    Eur J Clin Pharmacol; 2011 Sep; 67(9):889-98. PubMed ID: 21476064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.
    Shao H; Ren XM; Liu NF; Chen GM; Li WL; Zhai ZH; Wang DW
    J Clin Pharm Ther; 2010 Jun; 35(3):351-60. PubMed ID: 20831536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3.
    Chen Y; Chen L; Zhang H; Huang S; Xiong Y; Xia C
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):147-154. PubMed ID: 29498478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the
    Kim CO; Oh ES; Kim H; Park MS
    Drug Des Devel Ther; 2017; 11():503-512. PubMed ID: 28260863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.
    Lee HW; Lim MS; Lee J; Jegal MY; Kim DW; Lee WK; Jang IJ; Shin JG; Yoon YR
    J Clin Pharm Ther; 2012 Feb; 37(1):105-11. PubMed ID: 21208246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
    Zhang Y; Si D; Chen X; Lin N; Guo Y; Zhou H; Zhong D
    Br J Clin Pharmacol; 2007 Jul; 64(1):67-74. PubMed ID: 17298483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
    Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ragia G; Atzemian N; Maslarinou A; Manolopoulos VG
    Drug Metab Pers Ther; 2022 Dec; 37(4):347-352. PubMed ID: 36169244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.
    Dai DP; Wang SH; Geng PW; Hu GX; Cai JP
    Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis.
    Thakkar D; Dash RP
    Drug Des Devel Ther; 2017; 11():1263-1265. PubMed ID: 28461740
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Nov; 70(5):439-45. PubMed ID: 11719730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).
    Iwai M; Suzuki H; Ieiri I; Otsubo K; Sugiyama Y
    Pharmacogenetics; 2004 Nov; 14(11):749-57. PubMed ID: 15564882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects.
    Sana T; Aslam B; Aslam N; Ashraf MM; Ashraf A; Malik TA; Niazi SG; Tahir IM; RiazurRehman M; Ahmed H
    Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2321-2326. PubMed ID: 28167473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms.
    Wang R; Chen K; Wen SY; Li J; Wang SQ
    Clin Pharmacol Ther; 2005 Jul; 78(1):90-2. PubMed ID: 16003298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.